HCRT and Cognitive impairment: Therefore, further investigations on the role of orexin-A on symptoms presented by patients with cognitive impairment and dementia should be planned also for understating the clinical potential of including DORAs in the therapeutic armamentarium available for patients with neurocognitive disorders.